Literature DB >> 2458861

Substance P induces a cardiovascular defense reaction in the rat: pharmacological characterization.

T Unger1, S Carolus, G Demmert, D Ganten, R E Lang, C Maser-Gluth, H Steinberg, R Veelken.   

Abstract

In this study in conscious rats, we tested the hypothesis that substance P, a central pressor peptide and a potential transmitter substance of pain pathways, could be involved in the cardiovascular defense reaction that is typically associated with unpleasant sensory stimuli. The hemodynamic responses to centrally administered substance P were pharmacologically characterized. The increases in blood pressure and heart rate after intracerebroventricular injections of substance P were accompanied by mesenteric and renal vasoconstriction and hind limb vasodilation (pulsed-Doppler flow probes). The pressor and vasoconstrictor responses were attenuated by peripheral alpha 1-adrenoceptor blockade with prazosin but were not influenced by blockade of vascular vasopressin receptors with d(CH2)5Tyr(Me) arginine vasopressin (AVP). Cardiac beta 1-adrenoceptor blockade with metoprolol abolished the tachycardic and reduced the pressor responses. Substance P-induced hind limb vasodilation was not sensitive to intravenous atropine but was largely prevented by peripheral beta 2-adrenoceptor blockade with ICI 118,551. Thus, the substance P-induced pressor effects are mediated by alpha 1-adrenergic sympathetic vasoconstriction and beta 1-adrenergic cardiac stimulation, whereas the hind limb vasodilation is mainly due to beta 2-adrenergic stimulation. Substance P dose-dependently (0.01-10 micrograms i.c.v.) released oxytocin but not vasopressin or adrenocorticotropic hormone (ACTH) from the pituitary gland. High doses reduced basal ACTH levels. Together with the hemodynamic responses, a behavioral arousal reaction was observed, which included increased locomotion, grooming, scratching, and skin biting. Our results demonstrate that a neuropeptide can induce classic cardiovascular defense reaction.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2458861     DOI: 10.1161/01.res.63.4.812

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  15 in total

1.  The ventral tegmental area as a putative target for tachykinins in cardiovascular regulation.

Authors:  Kathleen Deschamps; Réjean Couture
Journal:  Br J Pharmacol       Date:  2005-07       Impact factor: 8.739

Review 2.  Substance P receptor antagonists in psychiatry: rationale for development and therapeutic potential.

Authors:  Inga Herpfer; Klaus Lieb
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

3.  Decreased renal haemodynamic response to inhibition of nitric oxide synthase in subtotally nephrectomized rats.

Authors:  J Wagner; A Wystrychowski; H Stauss; D Ganten; E Ritz
Journal:  Pflugers Arch       Date:  1995-06       Impact factor: 3.657

4.  The Hypothalamic-Pituitary-Adrenal Axis and Serotonin Metabolism in Individual Brain Nuclei of Mice with Genetic Disruption of the NK1 Receptor Exposed to Acute Stress.

Authors:  Juraj Culman; Stephan Mühlenhoff; Annegret Blume; Jürgen Hedderich; Ulf Lützen; Stephen P Hunt; Nadia M J Rupniak; Yi Zhao
Journal:  Cell Mol Neurobiol       Date:  2018-06-15       Impact factor: 5.046

5.  Modulation of cardiac activity by tachykinins in the rat substantia nigra.

Authors:  A Lessard; R Couture
Journal:  Br J Pharmacol       Date:  2001-12       Impact factor: 8.739

6.  Effects of the tachykinin NK1 receptor antagonist, RP 67580, on central cardiovascular and behavioural effects of substance P, neurokinin A and neurokinin B.

Authors:  J Culman; B Wiegand; H Spitznagel; S Klee; T Unger
Journal:  Br J Pharmacol       Date:  1995-03       Impact factor: 8.739

7.  Use of selective antagonists to dissociate the central cardiovascular and behavioural effects of tachykinins on NK1 and NK2 receptors in the rat.

Authors:  C Tschöpe; P Picard; J Culman; A Prat; K Itoi; D Regoli; T Unger; R Couture
Journal:  Br J Pharmacol       Date:  1992-11       Impact factor: 8.739

Review 8.  Innovative approaches for the development of antidepressant drugs: current and future strategies.

Authors:  Lee E Schechter; Robert H Ring; Chad E Beyer; Zoë A Hughes; Xavier Khawaja; Jessica E Malberg; Sharon Rosenzweig-Lipson
Journal:  NeuroRx       Date:  2005-10

9.  Comparative behavioural profile of centrally administered tachykinin NK1, NK2 and NK3 receptor agonists in the guinea-pig.

Authors:  O Piot; J Betschart; I Grall; S Ravard; C Garret; J C Blanchard
Journal:  Br J Pharmacol       Date:  1995-11       Impact factor: 8.739

10.  Upregulation of tachykinin NK-1 and NK-3 receptor binding sites in the spinal cord of spontaneously hypertensive rat: impact on the autonomic control of blood pressure.

Authors:  Frank Cloutier; Brice Ongali; Kathleen Deschamps; Jonathan Brouillette; Witold Neugebauer; Réjean Couture
Journal:  Br J Pharmacol       Date:  2006-05       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.